AzTrials
AzTrials

Irritable Bowel DiseasePIPPINCT07319078

Pain in Pediatric Patients - Internet Interventions for Disorders of Gut-brain Interaction

A study testing Gut-directed hypnotherapy and Cognitive-behavioral therapy in people with Irritable Bowel Disease and Functional Abdominal Pain - Not Otherwise Specified (FAP-NOS), run by Karolinska Institutet at 1 site in Sweden.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Many children and adolescents often experience long-lasting stomach pain. In many cases, this is due to disorders of gut-brain interaction (DGBI), such as irritable bowel syndrome (IBS), functional abdominal pain, and functional dyspepsia. Read more about this study

Who is it for?
Ages 8 to 17 years
What is being tested?
Gut-directed hypnotherapy and Cognitive-behavioral therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteSweden
Study dates
1 Dec 2025to Mar 2030
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Age 8-17 years
  • Basic somatic work-up completed (CRP/ESR, TGA, complete blood count, fecal calprotectin)
  • Confirmed DGBI diagnosis: IBS, functional abdominal pain, or functional dyspepsia (according to Rome IV criteria)
  • Any constipation must be treated according to current clinical guidelines, with stable laxative dosing for at least one month prior to referral
  • In cases of celiac disease, the participant must have followed a gluten-free diet for at least six months and TGA values must have normalized
  • For participants with a neuropsychiatric diagnosis treated with medication, at least two months must have passed since the last dose adjustment
  • At least one parent and the child/adolescent must be fluent in Swedish and willing to participate in both the educational program and treatment (regardless of randomization outcome), complete homework assignments, and respond to questionnaires

Who cannot join

  • Other organic disease that better explains the gastrointestinal symptoms
  • At referral assessment, psychiatric symptoms or psychosocial problems - such as severe bullying, high school absenteeism, or difficult family circumstances - are judged to be more prominent than the gastrointestinal problems and require more extensive, multiprofessional care than what the study can offer
  • Participants who have already completed gut-directed hypnotherapy or CBT

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Tea Soini, MD PhD contact

+46 766457611

tea.soini@ki.se

Frida Andersson, MSc contact

forskningsprojekt-pippi@ki.se

Sweden1 site, 1 recruiting
  • Sachs Children's Hospital

    Stockholm, 17164

    Tea Soini, MD PhD, +46855632613, forskningsprojekt-pippi@ki.se

    Recruiting

Other trials in Sweden

About this study

Official title: Internet-delivered Psychological Interventions for Pediatric Disorders of Gut-brain Interaction - a Randomised Controlled Study

Many children and adolescents often experience long-lasting stomach pain. In many cases, this is due to disorders of gut-brain interaction (DGBI), such as irritable bowel syndrome (IBS), functional abdominal pain, and functional dyspepsia. These conditions are caused by disrupted communication between the brain and the gut. They are linked to significant suffering, reduced quality of life, and higher school absenteeism. Psychological treatments such as cognitive behavioral therapy (CBT) have shown good effect, but waiting times within healthcare are often long. Therefore, there is a need for more accessible and cost-effective treatment alternatives.

The goal of this clinical trial is to explore whether gut-directed hypnotherapy, already used successfully in the Netherlands, can be implemented as a new treatment option in Swedish healthcare. In addition, the study will compare gut-directed hypnotherapy with internet-based CBT (iCBT) to learn which digital treatment works best for children and adolescents with DGBI.

Read more

Participants will:

Be children or adolescents between 8 and 17 years old.

First take part in a 4-week online education program called the "gut-school," which explains the stomach, the brain, and how symptoms can be managed.

If symptoms remain after the gut-school, be randomly assigned to one of two digital treatments:

iCBT (internet-based cognitive behavioral therapy). 10 week long.

Gut-directed hypnotherapy, delivered as audio recordings to be used at home. 12 week long.

Answer online survey questions before, during, and after treatment so researchers can follow their progress.

These two treatments have never been directly compared. By comparing them, researchers hope to learn not only which treatment works best overall, but also which treatment is most suitable for different participants. The long-term aim is to make gut-directed hypnotherapy, already successful in the Netherlands, available as a treatment option in Sweden.

Read the detailed description

Gut-directed hypnotherapy has shown promising results in several international studies for the treatment of disorders of gut-brain interaction (DGBI). The treatment builds on relaxation techniques, imagery, and sensory exercises focused on gastrointestinal symptoms. The goal is to improve both awareness of and control over gastrointestinal symptoms. Hypnotherapy is considered safe and has been shown to have very few side effects. International research, particularly from the Netherlands, demonstrates that hypnotherapy leads to better outcomes in both the short and the long term compared to conventional medical treatment. Importantly, home-based audio exercises have been shown to be just as effective as individual face-to-face hypnotherapy delivered by a therapist.

Background and preparation:The research group has already conducted a pilot study in Sweden to test the feasibility of gut-directed hypnotherapy for children with DGBI. In collaboration with Dutch experts, the treatment manual was translated into Swedish, culturally validated by child psychologists, and recorded in high-quality audio format. A secure study platform has been developed to deliver the treatments and collect outcomes, and comprehensive information material for families has been produced, including written texts, films, and audio.

The pilot study, initiated in 2023, showed promising results in the primary outcome measure, PedsQL Gastro, demonstrating improvements in gastrointestinal symptoms. In addition, the pilot provided valuable insights that have led to adjustments in treatment details in order to further optimize the intervention for children and families. These encouraging findings support the implementation of the planned randomized controlled trial and strengthen confidence in the treatment approach, which has now been further optimized based on pilot insights.

Aim: The aim of this randomized controlled trial (RCT) is twofold: first, to evaluate whether gut-directed hypnotherapy can be implemented as a digital treatment option within Swedish healthcare, and second, to compare its effectiveness with internet-based cognitive behavioral therapy (iCBT). These two evidence-based psychological treatments have never before been directly compared. The trial seeks to determine not only which treatment is most effective overall, but also which treatment may be best suited for different participants.

Study population:The RCT will recruit approximately 300 children and adolescents aged 8-17 years who meet diagnostic criteria for DGBI according to the Rome IV classification. Recruitment will take place at pediatric gastroenterology clinics and general pediatric units across Sweden, including both specialized gastroenterology centers and local child health clinics. Before enrollment, all families will talk with a study physician or study nurse to review inclusion and exclusion criteria, receive study information, and go through the principles of both treatment options.

Exposure: All participants will begin with a four-week digital education program called the "gut-school," designed to provide knowledge about the gut-brain interaction and strategies to manage symptoms. Participants who still report symptoms after completing the gut-school, and who are motivated to continue, will be eligible to enter the next phase of the study. These participants will be randomized in a 1:1 ratio to one of two active treatment arms. The hypnotherapy arm will consist of audio-based self-exercises performed at home every day for 12 weeks. The iCBT arm will consist of a structured, therapist-guided internet-based CBT program for abdominal pain, lasting 10 weeks. Both treatments will be delivered through the secure study platform, with the option to access materials via mobile devices.

Outcome: The primary outcome will be change in PedsQL Gastro, a validated questionnaire that measures gastrointestinal symptoms and their impact on daily life and quality of life. A clinically significant improvement will be defined in line with international recommendations. Secondary outcomes will include school attendance, psychological well-being, and health-related quality of life.

All outcomes will be collected both from children and from their parents, using parallel versions of the validated questionnaires. Data will be collected at baseline, every third week during treatment, immediately after completion, and at 6- and 24 months follow up, all through the secure digital platform with identification control.

A comprehensive health economic evaluation will be conducted, adopting a societal perspective to capture all relevant costs and consequences. Resource use will be assessed using the Trimbos and Institute of Technology Cost Questionnaire for Psychiatry (TIC-P), which measures direct medical, non-medical, and productivity-related costs over the preceding four weeks. Health-related quality of life will be assessed using PedsQL, which will be mapped to CHU9D to derive utilities and calculate QALYs (quality-adjusted life years). Both costs and QALYs will be discounted according to standard economic evaluation guidelines. Incremental cost-effectiveness ratios (ICERs) will be computed to compare interventions, and uncertainty will be explored. The analysis will adhere to international standards for trial-based economic evaluations.

Power:The research group has conducted a formal power analysis for the planned RCT. The analysis was based on results from the Swedish pilot study studies in both gut-directed hypnotherapy and cognitive behavioral therapy, including internet-based CBT. With these data as reference, the trial is designed to recruit 300 participants to ensure adequate power to detect clinically meaningful differences between treatment arms. The study is scheduled to run for two years, starting in autumn 2025.

Being tested
Gut-directed hypnotherapy, Cognitive-behavioral therapy
Keywords
gut-directed hypnotherapy, patient education, disorder of gut-brain intercation, cognitive behavioral therapy, functional abdominal pain, irritable bowel syndrome, randomised controlled trial
Medical subject headings
Irritable Bowel Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Gut-directed hypnotherapyBehavioural

    Also called Hypnotherapy, Hypnosis, Medical hypnotherapy

    The programme aims to alleviate gastrointestinal symptoms through deep relaxation and positive suggestions to alter the imagery related to the gut.

  • Cognitive-behavioral therapyBehavioural

    Also called CBT, Internet-CBT, Exposure-based CBT

    The programme is therapist-led and delivered via the internet. It includes exposure-based exercises that aim to improve gastrointestinal symptoms by decreasing avoidance behavior.

Study groups in NCT07319078
Study groupRoleWhat they receive
Gut-directed hypnotherapy via audiofilesExperimental12-week self-administered hypnotherapy programme. Participants gain access to five different hypnotherapy exercises via audio files and are instructed to listen to them at least once a day.
Receives: Behavioral: Gut-directed hypnotherapy
Internet-delivered cognitive behavioral therapyExperimentalThe participants receive access to a 10-week cognitive behavioral therapy (CBT) -programme.
Receives: Behavioral: Cognitive-behavioral therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Peds QL gastro

    Description: Short questionnaire gastrointestinal symptom scale. Minimum value 0, maximum value 100, higher score means better outcome.

    Measured: Assessments will be collected at baseline, after the gut-school (and before randomization), every third week during treatment (week 3, 6, 9 and 12), and at 6-month follow-up

Secondary outcomes (8)
  1. Pain frequency

    Assessed by asking participants how many minutes or hours they have experienced abdominal pain during each day of the same 7-day period. This will give an estimate of the overall duration of pain episodes in addition to their intensity.

    Measured: Assessments will be collected at baseline, after the gut-school (and before randomization), every third week during treatment (week 3, 6, 9 and 12), and at 6- and 24- month follow-up.

  2. Pain intensity

    Assessed with the Wong-Baker FACES Pain Rating Scale, a validated tool for children. At each measurement point, participants will rate their pain once daily for seven consecutive days, providing a weekly average of pain intensity.

    Measured: Assessments will be collected at baseline, after the gut-school (and before randomization), every third week during treatment (week 3, 6, 9 and 12), and at 6- and 24- month follow-up.

  3. Stress

    PAS pediatric stress questionnare. Minimum value 0, maximum value 44, higher score means worse outcome

    Measured: Assessments will be collected after the gut-school (and before randomization), every third week during treatment (week 3, 6, 9 and 12), and at 6-month follow-up

  4. Gastrointestinal symtom -related anxiety

    BRQ-C questionnare. Minimum value 11, maximum value 77, higher score means worse outcome.

    Measured: Assessments will be collected at baseline, after the gut-school (and before randomization), every third week during treatment (week 3, 6, 9 and 12), and at 6-month follow-up.

  5. GI symptom specific anxiety

    VSI: Visceral sensitivity index short scale. Minimum value 0, maximum value 35, higher score means worse outcome.

    Measured: Assessments will be collected after the gut-school (and before randomization), every third week during treatment (week 3, 6, 9 and 12), and at 6-month follow-up

  6. Quality of life

    Peds-QL- QOL. Minimum value 0, maximum value 100, higher score means better outcome.

    Measured: Assessments will be collected at baseline, after the gut-school (and before randomization), every third week during treatment (week 3, 6, 9 and 12), and at 6-month follow-up

  7. Adequate relief

    SAQ. Minimum value 0, maximum value 7, higher score means better outcome

    Measured: Assessments will be collected after the gut-school (before randomization), every third week during treatment (week 3, 6, 9 and 12), and at 6-month follow-up

  8. Self efficacy

    This questionnaire measures how confident a person feels in managing gastrointestinal symptoms, such as abdominal pain, discomfort, or nausea. Confidence is rated on a scale from 0 ("not at all confident") to 100 ("completely confident"). The aim is to capture self-efficacy in handling symptoms without relying on medication.

    Measured: Assessments will be collected after the gut-school (and before randomization), every third week during treatment (week 3, 6, 9 and 12), and at 6-month follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jan 2026
  2. Study start1 Dec 2025
  3. Primary completionMar 2030 (estimated)
  4. Study completionMar 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
All participants first undergo an online structured patient education program. Thereafter, the participants who still fulfill the diagnostic criteria will be randomised to two treatment arms: 1) internet-delivered cognitive behavioral therapy or 2) gut-directed hypnotherapy via audiofiles
Masking
None (open label)
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07319078
Sponsor's protocol ID
2025-04544-02
Other IDs
2025
Acronym
PIPPI
Status last verified
Dec 2025
First submitted
7 Dec 2025
Last updated
6 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Gut-directed hypnotherapy and Cognitive-behavioral therapy in people with Irritable Bowel Disease and Functional Abdominal Pain - Not Otherwise Specified (FAP-NOS), run by Karolinska Institutet at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 6 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Tea Soini, MD PhD (+46 766457611, tea.soini@ki.se), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Peds QL gastro (time frame: Assessments will be collected at baseline, after the gut-school (and before randomization), every third week during treatment (week 3, 6, 9 and 12), and at 6-month follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in